266 related articles for article (PubMed ID: 27680189)
1. [Implications of PI-RADS Version 1 and Updated Version 2 on the Scoring of Prostatic Lesions in Multiparametric MRI].
Haas M; Günzel K; Penzkofer T; Maxeiner A; Fischer T; Miller K; Hamm B; Asbach P; Cash H
Aktuelle Urol; 2016 Sep; 47(5):383-7. PubMed ID: 27680189
[TBL] [Abstract][Full Text] [Related]
2. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
[TBL] [Abstract][Full Text] [Related]
3. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
[TBL] [Abstract][Full Text] [Related]
4. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results.
Auer T; Edlinger M; Bektic J; Nagele U; Herrmann T; Schäfer G; Aigner F; Junker D
World J Urol; 2017 May; 35(5):687-693. PubMed ID: 27510762
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
[TBL] [Abstract][Full Text] [Related]
7. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
8. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
[TBL] [Abstract][Full Text] [Related]
9. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.
Giannarini G; Girometti R; Crestani A; Rossanese M; Calandriello M; Cereser L; Bednarova S; Battistella C; Sioletic S; Zuiani C; Valotto C; Ficarra V
Urology; 2019 Jan; 123():191-197. PubMed ID: 30273613
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.
Becker AS; Cornelius A; Reiner CS; Stocker D; Ulbrich EJ; Barth BK; Mortezavi A; Eberli D; Donati OF
Eur J Radiol; 2017 Sep; 94():58-63. PubMed ID: 28941761
[TBL] [Abstract][Full Text] [Related]
13. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
14. Impact of Clinical History on Maximum PI-RADS Version 2 Score: A Six-Reader 120-Case Sham History Retrospective Evaluation.
Shankar PR; Kaza RK; Al-Hawary MM; Masch WR; Curci NE; Mendiratta-Lala M; Sakala MD; Johnson TD; Davenport MS
Radiology; 2018 Jul; 288(1):158-163. PubMed ID: 29664338
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Gündoğdu E; Emekli E; Kebapçı M
Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
[TBL] [Abstract][Full Text] [Related]
16. Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using whole-mount histology as the standard of reference.
Girometti R; Giannarini G; Greco F; Isola M; Cereser L; Como G; Sioletic S; Pizzolitto S; Crestani A; Ficarra V; Zuiani C
J Magn Reson Imaging; 2019 Feb; 49(2):546-555. PubMed ID: 30187600
[TBL] [Abstract][Full Text] [Related]
17. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
[TBL] [Abstract][Full Text] [Related]
19. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
Yilmaz EC; Lin Y; Belue MJ; Harmon SA; Phelps TE; Merriman KM; Hazen LA; Garcia C; Johnson L; Lay NS; Toubaji A; Merino MJ; Patel KR; Parnes HL; Law YM; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2024 Jan; 222(1):e2329964. PubMed ID: 37729551
[No Abstract] [Full Text] [Related]
20. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
